William C. Patt
Deciphera Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Nitric Oxide and Endothelin Effects, Receptor Mechanisms and Signaling, Eicosanoids and Hypertension Pharmacology, Renin-Angiotensin System Studies, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors(1992)371 cited
- → Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants(2019)275 cited
- → Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036(2011)204 cited
- → Discovery of a Novel Series of Orally Active Non-Peptide Endothelin-A (ETA) Receptor-Selective Antagonists(1995)109 cited
- → Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2(2015)76 cited
- → Reactions of lithiooxazole(1991)66 cited
- → N6-Bicycloalkyladenosines with unusually high potency and selectivity for the adenosine A1 receptor(1989)57 cited
- → Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis(2009)48 cited
- → Ribose-modified adenosine analogs as adenosine receptor agonists(1986)48 cited
- → Structure−Activity Relationships in a Series of Orally Active γ-Hydroxy Butenolide Endothelin Antagonists(1997)46 cited